Biogen’s Growth Portfolio has overtaken declining MS revenue, creating a catalyst-rich turnaround valued at only 12.0x–12.5x forward earnings.
Overview
Biogen is a global neuroscience and specialty biopharmaceutical company pivoting from its eroding multiple sclerosis franchise toward higher-growth rare disease, immunology, Alzheimer’s, and royalty assets. **The turnaround is becoming visible in reported results:** Q2 2026 revenue increased 3% year over year to $2,736.0 million, exceeding the $2,430.0–$2,500.0 million consensus range, while the Growth Portfolio surpassed MS revenue. Management reversed prior full-year guidance for a mid-single-digit revenue decline and now expects mid-single-digit revenue growth in 2026. GAAP diluted EPS fell 85% to $0.66 because of acquisition amortization, $173.3 million of first-half restructuring costs, and a $164.0 million acquired IPR&D charge, but adjusted diluted EPS of $3.60 exceeded the $3.17 consensus estimate. The shares traded near $216 after rising 5.45% on July 29, 2026, versus a 52-week range of $124.56–$219.72. **At 12.0x–12.5x forward P/E, valuation remains compressed** if Leqembi, Skyclarys, Zurzuvae, Apellis assets, and the late-stage pipeline replace MS cash flows. Key catalysts are Leqembi Iqlik adoption, litifilimab Phase 3 data in Q4 2026, and 2027 felzartamab and zorevunersen readouts.